Torasemide,a new loop diuretics
Torasemide,a new loop diuretics
复制标题
DOI：
--
复制
发表时间：
2003
期刊：
影响因子：
--
通讯作者：
Song Zhen
中科院分区：
文献类型：
--
作者：
Song Zhen
本文综述了托拉塞米的药理学、药动学、临床疗效、不良反应及药物经济学。托拉塞米属于吡啶磺酰脲类髓袢利尿剂。它的主要活动部位是亨利氏袢的粗升支，在那里它阻断钠和氯的主动再吸收，导致利尿、尿钠排泄和其他作用。托拉塞米生物利用度高，半衰期相对较长。它与蛋白质高度结合。临床试验表明，托拉塞米可有效治疗慢性肾功能衰竭、肝功能障碍或充血性心力衰竭（CHF）患者的高血压、水肿和其他症状。托拉塞米有轻微的副作用。药物经济学分析表明，托拉塞米可能通过减少住院和再住院来降低CHF的总体治疗费用。
The pharmacology, pharmacokinetics, clinical eff icacy, adverse effects, and pharmaco economics of torasemide are reviewed. Torasemide belongs to the pyridine-sulfonylurea class of loop diuretics. Its primary site of activity is the thick ascending limb of the loop of Henle, where it blockes active reaborption of sodium and chloride, resulting in diuresis, natriuresis, and other effects. Torasemide has high bioavailability,a relatively long half-life. It is highly protein bound. Clinical trials indicate that torasemide is effective in the treatment of hypertension and of edema and other symptoms in patients with chronic renal failure,hepatic dysfunction,or congestive heart failure(CHF) . Torasemide has mild, adverse effects. Pharmacoeconomic analysis has shown that torasemide is likely to reduce overall treatment costs of CHF by reducing hospital admission and readmission.